J Bone Metab.  2014 Feb;21(1):69-75.

Serum Sclerostin in Hepatitis C Virus Infected Patients

Affiliations
  • 1Department of Internal Medicine, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Canary Islands, Spain. egonrey@ull.es
  • 2Department of Laboratory, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Canary Islands, Spain.

Abstract

BACKGROUND
Sclerostin inhibits osteoblast functions, differentiations, and survival rates. As an endogenous inhibitor of the Wnt/beta-catenin pathway, the sclerostin should be related to decreased bone masses, although several studies indicate opposite results. In addition, it may be related to insulin resistances and carbohydrate metabolisms, a relation shared with other markers of bone metabolisms, such as osteocalcin. Hepatitis C virus (HCV) infected patients may present osteoporosis, and frequently show liver steatosis, which is a consequence of insulin resistance. The behaviour of sclerostin in these patients is yet unknown. The aim of this work is to analyse the relationships between serum sclerostin and osteocalcin levels and bone mineral density (BMD), liver functions, the intensity of liver steatosis and biochemical markers of bone homeostasis and insulin resistance in HCV-infected patients.
METHODS
Forty HCV patients with 20 years of age and gender-matching controls were included in this study and underwent bone densitometry. Serum sclerostin, osteocalcin, collagen telopeptide, adiponectin, leptin, insulin, resistin, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 were determined. Liver fat was histomorphometrically assessed.
RESULTS
Sclerostin levels were slightly higher in patients than in controls, and were directly related to BMD at different parts of the skeleton, also to the serum telopeptide, and to the liver steatosis and TNF-alpha. On the contrary, osteocalcin showed a significant direct relationship with serum adiponectin, and an inverse one with IL-6.
CONCLUSIONS
Serum sclerostin levels were within the normal range in HCV patients, and correlated directly with BMD and serum telopeptide. In addition, the relationships of sclerostin and osteocalcin with variables associated with insulin resistance suggested the role of bones for intermediary metabolisms.

Keyword

Fatty liver; Hepacivirus; Insulin resistance; Osteocalcin

MeSH Terms

Adiponectin
Biomarkers
Bone Density
Collagen
Densitometry
Fatty Liver
Hepacivirus*
Hepatitis C*
Hepatitis*
Homeostasis
Humans
Insulin
Insulin Resistance
Interleukin-6
Interleukins
Leptin
Liver
Osteoblasts
Osteocalcin
Osteoporosis
Reference Values
Resistin
Skeleton
Survival Rate
Tumor Necrosis Factor-alpha
Adiponectin
Collagen
Insulin
Interleukin-6
Interleukins
Leptin
Osteocalcin
Resistin
Tumor Necrosis Factor-alpha

Reference

1. van Bezooijen RL, Papapoulos SE, Löwik CW. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest. 2005; 28:8 Suppl. 15–17.
2. Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009; 24:171–178.
Article
3. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280:19883–19887.
Article
4. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97:3744–3750.
Article
5. Ardawi MS, Rouzi AA, Qari MH. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012; 97:3691–3699.
Article
6. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199:805–814.
Article
7. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19:1842–1844.
Article
8. Sheng Z, Tong D, Ou Y, et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012; 76:797–801.
Article
9. Faje AT, Fazeli PK, Katzman DK, et al. Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone. 2012; 51:474–479.
Article
10. García-Martín A, Rozas-Moreno P, Reyes-Garcia R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97:234–241.
Article
11. González-Reimers E, Martín-González C, de la Vega-Prieto MJ, et al. Serum sclerostin in alcoholics: a pilot study. Alcohol Alcohol. 2013; 48:278–282.
Article
12. Cejka D, Jäger-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012; 27:226–230.
Article
13. Polyzos SA, Anastasilakis AD, Bratengeier C, et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012; 23:1171–1176.
Article
14. Yavropoulou MP, van Lierop AH, Hamdy NA, et al. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012; 51:153–157.
Article
15. Morales-Santana S, García-Fontana B, García-Martín A, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013; 36:1667–1674.
Article
16. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97:1737–1744.
Article
17. Starup-Linde J. Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol (Lausanne). 2013; 4:21.
Article
18. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology. 2011; 140:809–817.
Article
19. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998; 29:495–501.
Article
20. Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabolism: a two-way street. Arch Biochem Biophys. 2010; 503:2–10.
Article
21. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998; 28:695–699.
Article
22. Corazza GR, Trevisani F, Di Stefano M, et al. Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci. 2000; 45:1392–1399.
23. Carey EJ, Balan V, Kremers WK, et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003; 9:1166–1173.
Article
24. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005; 11:1843–1847.
Article
25. Hofmann WP, Kronenberger B, Bojunga J, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat. 2008; 15:790–796.
26. Nanda KS, Ryan EJ, Murray BF, et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol. 2009; 7:894–899.
Article
27. Pelazas-González R, González-Reimers E, Alemán-Valls MR, et al. Bone alterations in hepatitis C virus infected patients. Eur J Intern Med. 2013; 24:92–96.
Article
28. Manganelli P, Giuliani N, Fietta P, et al. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol. 2005; 24:296–300.
Article
29. Fiore CE, Riccobene S, Mangiafico R, et al. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. Osteoporos Int. 2005; 16:2180–2184.
Article
30. Shaker JL, Reinus WR, Whyte MP. Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab. 1998; 83:93–98.
Article
31. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95:2248–2253.
Article
32. Wieczorek-Baranowska A, Nowak A, Pilaczyńska-Szcześniak Ł. Osteocalcin and glucose metabolism in postmenopausal women subjected to aerobic training program for 8 weeks. Metabolism. 2012; 61:542–545.
Article
33. Confavreux CB, Szulc P, Casey R, et al. Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. J Clin Endocrinol Metab. 2013; 98:1084–1092.
Article
34. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257:79–83.
Article
35. Ogawa-Furuya N, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus. Osteoporos Int. 2013; 24:2223–2230.
Article
Full Text Links
  • JBM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr